Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 3, 2012, Pages 1152-1161

  Keane, Pearse A ^a   Heussen, Florian M ^b,c   Ouyang, Yanling ^b,d   Mokwa, Nils ^b   Walsh, Alexander C ^b   Tufail, Adnan ^a   Sadda, Srinivas R ^b   Patel, Praveen J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860614467     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8130     Document Type: Article

References (55)

1. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116:S15-S23.
2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
3. Tufail AT, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study. BMJ. 2010;340:c2459.
4. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011; 118:663-671.
5. Lalwani G, Rosenfeld P, Fung A, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.e1.
6. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
7. Keane PA, Sadda SR. Imaging chorioretinal vascular disease. Eye. 2010;24:422-427.
8. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3115-3120.
9. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology. 2008; 115:e39-e46.
10. Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina. 2010;30:1390-1399.
11. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, Group MS. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868-1875.
12. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
13. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92:361-364.
14. Keane PA, Liakopoulos S, Chang KT, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology. 2008;115:2206-2214.
15. Keane PA, Patel PJ, Ouyang Y, et al. Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51: 5431-5437.
16. Kashani AH, Keane PA PA, Dustin L, Walsh AC, Sadda SR. Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3366-3373.
17. Alasil T, Keane PA, Updike JF, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology. 2010;117:2379-2386.
18. Csaky KG, Richman EA, Ferris FL. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49:479-489.
19. Lloyd R, Harris J, Wadhwa S, Chambers W. Food and Drug Administration approval process for ophthalmic drugs in the US. Curr Opin Ophthalmol. 2008;19:190-194.
20. Kaiser PK. Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? Br J Ophthalmol. 2010;94:143-145.
21. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina. 2010;30:1350-1367.
22. Patel P, Bunce C, Tufail AT, Abc Trial Investigators O. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age-related macular degeneration: clinical trial design. Trials. 2008;9:56.
23. Sadda SR, Keane PA, Ouyang Y, Updike JF, Walsh AC. Impact of scanning density on measurements from spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51: 1071-1078.
24. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2007; 48:4300-4307.
25. Sadda SR, Joeres S, Wu Z, et al. Error correction and quantitative subanalysis of optical coherence tomography data using computerassisted grading. Invest Ophthalmol Vis Sci. 2007;48:839-848.
26. Sadda SR, Wu Z, Walsh AC, et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology. 2006;113:285-293.
27. Patel PJ, Chen FK, da Cruz L, Tufail AT. Segmentation error in Stratus optical coherence tomography for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:399-404.
28. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
29. Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45:3435-3441.
30. Dingemanse J, Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet. 2007;46:713-737.
31. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009;24:16-24.
32. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1-S7.
33. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
34. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
35. Joeres S, Kaplowitz K, Brubaker JW, et al. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology. 2008;115:347-354.
36. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF inhibition in ocular neovascularization clinical trial group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
37. Emerson GG, Flaxel CJ, Lauer AK, et al. Optical coherence tomography findings during pegaptanib therapy for neovascular agerelated macular degeneration. Retina. 2007;27:724-729.
38. Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv Ophthalmol. 2007;52:227-243.
39. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
40. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
41. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169: 681-691.
42. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
43. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187.
44. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
45. Keane PA, Aghaian E, Ouyang Y, Chong LP, Sadda SR. Acute severe visual decrease after photodynamic therapy with verteporfin: spectral- domain OCT features. Ophthalmic Surg Lasers Imaging. 2010; 41(suppl):S85-S88.
46. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology. 2005;112:2061-2069.
47. Liakopoulos S, Ongchin S, Bansal A, et al. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:548-5054.
48. Han IC, Jaffe GJ. Evaluation of artifacts associated with macular spectral-domain optical coherence tomography. Ophthalmology. 2010;117:1177-1189.e1174.
49. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
50. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Ret Eye Res. 2008;27:45-88.
51. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2011;52:1599-1605.
52. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50:2376-2383.
53. Patel PJ, Chen FK, Ikeji F, et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:1084-1088.
54. Keane PA, Liakopoulos S, Jivrajka RV, et al. Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3378-3385.
55. Do DV. Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology. 2009;116:S24-S26.